Magno Sanol may be available in the countries listed below.
Magnesium Oxide heavy (a derivative of Magnesium Oxide) is reported as an ingredient of Magno Sanol in the following countries:
International Drug Name Search
Tantalick may be available in the countries listed below.
Dilazep dihydrochloride (a derivative of Dilazep) is reported as an ingredient of Tantalick in the following countries:
International Drug Name Search
Syntofulvin may be available in the countries listed below.
Griseofulvin is reported as an ingredient of Syntofulvin in the following countries:
International Drug Name Search
Vitamin B1-Hevert may be available in the countries listed below.
Thiamine hydrochloride (a derivative of Thiamine) is reported as an ingredient of Vitamin B1-Hevert in the following countries:
International Drug Name Search
Tirocular may be available in the countries listed below.
Acetylcysteine is reported as an ingredient of Tirocular in the following countries:
International Drug Name Search
brand of augmented betamethasone dipropionate1
Ointment 0.05%
(potency expressed as betamethasone)
For Dermatologic Use Only–Not for Ophthalmic Use
PRODUCT INFORMATION
Diprolene® (augmented betamethasone dipropionate) Ointment contains betamethasone dipropionate USP, a synthetic adrenocorticosteroid, for dermatologic use. Betamethasone, an analog of prednisolone, has a high degree of corticosteroid activity and a slight degree of mineralocorticoid activity. Betamethasone dipropionate is the 17, 21-dipropionate ester of betamethasone.
Chemically, betamethasone dipropionate is 9-fluoro-11β, 17,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate, with the empirical formula C28H37FO7, a molecular weight of 504.6 and the following structural formula:
It is a white to creamy-white, odorless powder insoluble in water; freely soluble in acetone and in chloroform; sparingly soluble in alcohol.
Each gram of Diprolene Ointment 0.05% contains 0.643 mg betamethasone dipropionate USP (equivalent to 0.5 mg betamethasone), in a vehicle of propylene glycol; propylene glycol stearate; white wax; and white petrolatum.
The corticosteroids are a class of compounds comprising steroid hormones secreted by the adrenal cortex and their synthetic analogs. In pharmacologic doses, corticosteroids are used primarily for their anti-inflammatory and/or immunosuppressive effects.
Topical corticosteroids, such as betamethasone dipropionate, are effective in the treatment of corticosteroid-responsive dermatoses primarily because of their anti-inflammatory, antipruritic, and vasoconstrictive actions. However, while the physiologic, pharmacologic, and clinical effects of the corticosteroids are well known, the exact mechanisms of their actions in each disease are uncertain. Betamethasone dipropionate, a corticosteroid, has been shown to have topical (dermatologic) and systemic pharmacologic and metabolic effects characteristic of this class of drugs.
The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings (see DOSAGE AND ADMINISTRATION).
Topical corticosteroids can be absorbed through normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids (see DOSAGE AND ADMINISTRATION).
Once absorbed through the skin, topical corticosteroids enter pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees, are metabolized primarily in the liver, and excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
Studies performed with Diprolene® Ointment indicate that it is in the super-high range of potency as compared with other topical corticosteroids.
Diprolene® Ointment is a super-high potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age and older. The total dose should not exceed 50 g per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis.
Diprolene® Ointment is contraindicated in patients who are hypersensitive to betamethasone dipropionate, to other corticosteroids, or to any ingredient in this preparation.
Systemic absorption of topical corticosteroids has produced reversible HPA axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.
Conditions which augment systemic absorption include the application of the more potent corticosteroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Use of more than one corticosteroid-containing product at the same time may increase total systemic glucocorticoid exposure (see DOSAGE AND ADMINISTRATION).
Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area should be evaluated periodically for evidence of HPA axis suppression by using the urinary-free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.
Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Patients should not be treated with amounts of Diprolene® Ointment greater than 50 g per week because of the potential for the drug to suppress HPA axis. Patients receiving super-potent corticosteroids should not be treated for more than 2 weeks at a time and only small areas should be treated at any one time due to the increased risk of HPA suppression.
At 14 g per day Diprolene Ointment was shown to depress the plasma levels of adrenal cortical hormones following repeated application to diseased skin in patients with psoriasis. These effects were reversible upon discontinuation of treatment. At 7 g per day Diprolene Ointment was shown to cause minimal inhibition of the HPA axis when applied 2 times daily for 2 to 3 weeks in healthy patients and in patients with psoriasis and eczematous disorders.
With 6 to 7 g of Diprolene Ointment applied once daily for 3 weeks, no significant inhibition of the HPA axis was observed in patients with psoriasis and atopic dermatitis, as measured by plasma cortisol and 24-hour urinary 17-hydroxy-corticosteroid levels. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.
Pediatric patients may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (see PRECAUTIONS, Pediatric Use section).
If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.
In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.
Diprolene Ointment should not be used in the treatment of rosacea or perioral dermatitis, and it should not be used on the face, groin, or in the axillae.
Patients using topical corticosteroids should receive the following information and instructions. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.
The following tests may be helpful in evaluating patients for HPA axis suppression:
Long-term animal studies have not been performed to evaluate the carcinogenic potential of betamethasone dipropionate. Betamethasone was negative in the bacterial mutagenicity assay (Salmonella typhimurium and Escherichia coli), and in the mammalian cell mutagenicity assay (CHO/HGPRT). It was positive in the in vitro human lymphocyte chromosome aberration assay, and equivocal in the in vivo mouse bone marrow micronucleus assay. This pattern of response is similar to that of dexamethasone and hydrocortisone. Studies in rabbits, mice, and rats using intramuscular doses up to 1, 33, and 2 mg/kg, respectively, resulted in dose-related increases in fetal resorptions in rabbits and mice.
Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. Betamethasone dipropionate has been shown to be teratogenic in rabbits when given by the intramuscular route at doses of 0.05 mg/kg. This dose is approximately 0.2 times the human topical dose of Diprolene Ointment in mg/m2 of body surface area, assuming 100% absorption and the use in a 60 kg person of 7 g per day. The abnormalities observed included umbilical hernias, cephalocele, and cleft palate. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Diprolene Ointment should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when Diprolene Ointment is administered to a nursing woman.
Use of Diprolene Ointment, 0.05%, in pediatric patients 12 years of age and younger is not recommended (see CLINICAL PHARMACOLOGY and ADVERSE REACTIONS).
Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio.
Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and an absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Chronic corticosteroid therapy may interfere with the growth and development of children.
Clinical studies of Diprolene Ointment included 225 subjects who were 65 years of age and over and 46 subjects who were 75 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients. However, greater sensitivity of some older individuals cannot be ruled out.
The local adverse reactions which were reported with Diprolene® Ointment during controlled clinical trials were as follows: erythema, folliculitis, pruritus, and vesiculation each occurring in less than 1% of patients.
The following additional local adverse reactions have been reported with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids. These reactions are listed in an approximately decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, and miliaria.
Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.
Topically applied Diprolene® Ointment can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS).
Apply a thin film of Diprolene® Ointment to the affected skin once or twice daily.
Diprolene Ointment is a super-high potency topical corticosteroid. Treatment with Diprolene Ointment should be limited to 50 g per week.
As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.
Diprolene Ointment should not be used with occlusive dressings. Diprolene Ointment should not be applied to the diaper area if the patient requires diapers or plastic pants as these garments may constitute occlusive dressing.
Diprolene® Ointment 0.05% is supplied in 15-g (NDC 0085-0575-02) and 50-g (NDC 0085-0575-05) tubes; boxes of one.
Store at 25°C (77°F); excursions permitted to 15°–30°C (59°–86°F) [see USP Controlled Room Temperature].
Manufactured by: Schering-Plough Canada, Inc., Pointe Claire, Quebec, Canada
Distributed by: Schering Corporation, a subsidiary of
MERCK & CO., INC.
Whitehouse Station, NJ 08889, USA
Copyright © 1983, 2004 Schering Corporation, a subsidiary of Merck & Co., Inc.
All rights reserved.
Rev. 8/10
34489700T
NDC 0085-0575-05
50 g
Diprolene®
brand of augmented
betamethasone
dipropionate*
Ointment
0.05%
(Potency expressed
as betamethasone)
*Vehicle augments the
penetration of the steroid.
O
For dermatologic
use only.
Not for
ophthalmic use.
Rx only
| Diprolene betamethasone dipropionate ointment | ||||||||||||||||||||||||
| ||||||||||||||||||||||||
| ||||||||||||||||||||||||
| ||||||||||||||||||||||||
| ||||||||||||||||||||||||
| ||||||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| NDA | NDA018741 | 06/23/2011 | |
| Labeler - Schering Corporation (001317601) |
| Establishment | |||
| Name | Address | ID/FEI | Operations |
| SCHERING CANADA INC | 207093332 | MANUFACTURE | |
Octeniderm may be available in the countries listed below.
Octenidine dihydrochloride (a derivative of Octenidine) is reported as an ingredient of Octeniderm in the following countries:
International Drug Name Search
Rinter may be available in the countries listed below.
Risperidone is reported as an ingredient of Rinter in the following countries:
International Drug Name Search
Rastocin may be available in the countries listed below.
Doxorubicin hydrochloride (a derivative of Doxorubicin) is reported as an ingredient of Rastocin in the following countries:
International Drug Name Search
Sizonil may be available in the countries listed below.
Trifluoperazine hydrochloride (a derivative of Trifluoperazine) is reported as an ingredient of Sizonil in the following countries:
International Drug Name Search
Axépim may be available in the countries listed below.
Cefepime Hydrochloride (a derivative of Cefepime) is reported as an ingredient of Axépim in the following countries:
International Drug Name Search
Irinotecan Hospira may be available in the countries listed below.
Irinotecan hydrochloride trihydrate (a derivative of Irinotecan) is reported as an ingredient of Irinotecan Hospira in the following countries:
International Drug Name Search
Lamifen may be available in the countries listed below.
Terbinafine hydrochloride (a derivative of Terbinafine) is reported as an ingredient of Lamifen in the following countries:
International Drug Name Search
Vexylan may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Xylazine hydrochloride (a derivative of Xylazine) is reported as an ingredient of Vexylan in the following countries:
International Drug Name Search
Cébénicol may be available in the countries listed below.
Chloramphenicol is reported as an ingredient of Cébénicol in the following countries:
International Drug Name Search
Minro may be available in the countries listed below.
Mequitazine is reported as an ingredient of Minro in the following countries:
International Drug Name Search
Medoclazide may be available in the countries listed below.
Gliclazide is reported as an ingredient of Medoclazide in the following countries:
International Drug Name Search
Snow E Muscle may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Tocopherol, α- acetate (a derivative of Tocopherol, α-) is reported as an ingredient of Snow E Muscle in the following countries:
International Drug Name Search
Dolocap may be available in the countries listed below.
Tramadol hydrochloride (a derivative of Tramadol) is reported as an ingredient of Dolocap in the following countries:
International Drug Name Search
Hepaflush may be available in the countries listed below.
Heparin sodium salt (a derivative of Heparin) is reported as an ingredient of Hepaflush in the following countries:
International Drug Name Search
Siesta may be available in the countries listed below.
Bromazepam is reported as an ingredient of Siesta in the following countries:
International Drug Name Search
Ciprobel may be available in the countries listed below.
Ciprofloxacin is reported as an ingredient of Ciprobel in the following countries:
Ciprofloxacin hydrochloride (a derivative of Ciprofloxacin) is reported as an ingredient of Ciprobel in the following countries:
International Drug Name Search
Asthalin may be available in the countries listed below.
Salbutamol is reported as an ingredient of Asthalin in the following countries:
Salbutamol sulfate (a derivative of Salbutamol) is reported as an ingredient of Asthalin in the following countries:
International Drug Name Search
Generic Name: phenylpropanolamine (fen ill proe pa NOLE a meen)
Brand Names: Acutrim 16 Hour, Acutrim II, Maximum Strength, Acutrim Late Day, Control, Dexatrim, Empro, Mega-Trim, Phenyldrine, Propagest, Propan, Rhindecon, Westrim, Westrim LA
Phenylpropanolamine is a decongestant. It works by constricting (shrinking) blood vessels (veins and arteries) in your body. Constriction of blood vessels in your sinuses, nose, and chest allows drainage of those areas, which decreases congestion.
Phenylpropanolamine is used to treat the congestion associated with allergies, hay fever, sinus irritation, and the common cold. Phenylpropanolamine also causes a decrease in appetite and is used in some over-the-counter diet aids.
Phenylpropanolamine has been associated with an increased risk of hemorrhagic stroke (bleeding into the brain or into tissue surrounding the brain) in women. Men may also be at risk. Although the risk of hemorrhagic stroke is low, the U.S. Food and Drug Administration (FDA) recommends that consumers not use any products that contain phenylpropanolamine.
Phenylpropanolamine may also be used for purposes other than those listed in this medication guide.
Phenylpropanolamine has been associated with an increased risk of hemorrhagic stroke (bleeding into the brain or into tissue surrounding the brain) in women. Men may also be at risk. Although the risk of hemorrhagic stroke is low, the U.S. Food and Drug Administration (FDA) recommends that consumers not use any products that contain phenylpropanolamine.
Do not take phenylpropanolamine for longer than 7 days if your condition does not improve or if your symptoms are accompanied by a high fever.
Do not take phenylpropanolamine if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), phenelzine (Nardil), or tranylcypromine (Parnate) in the last 14 days. A very dangerous drug interaction could occur, leading to serious side effects.
Before taking this medication, tell your doctor if you have
high blood pressure;
any type of heart disease, hardening of the arteries, or irregular heartbeat;
thyroid problems;
diabetes;
glaucoma or increased pressure in your eye;
an enlarged prostate or difficulty urinating; or
liver or kidney disease.
You may not be able to take phenylpropanolamine, or you may require a lower dose or special monitoring during treatment if you have any of the conditions listed above.
Take phenylpropanolamine exactly as directed by your doctor, or follow the instructions that accompany the package. If you do not understand these directions, ask your pharmacist, nurse, or doctor to explain them to you.
If your symptoms are accompanied by a high fever, or if they do not improve in 7 days, see your doctor.
Take the missed dose as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and take only your next regularly scheduled dose. Do not take a double dose of this medication.
Symptoms of a phenylpropanolamine overdose include extreme tiredness, sweating, dizziness, a slow heart beat, and a coma.
If you experience any of the following serious side effects from this medication, stop taking phenylpropanolamine and seek emergency medical attention:
an allergic reaction (difficulty breathing; closing of your throat; swelling of your lips, tongue, or face; or hives);
seizures;
unusual behavior or hallucinations; or
an irregular or fast heartbeat.
Other, less serious side effects may be more likely to occur. Continue to take phenylpropanolamine and talk to your doctor if you experience
dizziness, lightheadedness, or drowsiness;
headache;
insomnia;
anxiety;
tremor (shaking) or restlessness;
nausea or vomiting; or
sweating.
Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome.
Do not take phenylpropanolamine if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), phenelzine (Nardil), or tranylcypromine (Parnate) in the last 14 days. A very dangerous drug interaction could occur, leading to serious side effects.
Phenylpropanolamine may also interact with the following medicines:
furazolidone (Furoxone);
guanethidine (Ismelin);
indomethacin (Indocin);
methyldopa (Aldomet);
bromocriptine (Parlodel);
caffeine in cola, tea, coffee, chocolate, and other products;
theophylline (Theo-Dur, Theochron, Theolair, others);
Drugs other than those listed here may also interact with phenylpropanolamine. Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines.
Phenylpropanolamine is available over the counter under the brand name Propagest, and with a prescription under the brand name Rhindecon. Other brand or generic formulations may also be available. Ask your pharmacist any questions you have about this medication, especially if it is new to you.
Propagest 25 mg--oval, white, scored tablets
Rhindecon 75 mg--timed-release capsules
See also: Dexatrim side effects (in more detail)
Mesagin may be available in the countries listed below.
Mesalazine is reported as an ingredient of Mesagin in the following countries:
International Drug Name Search
Magnogene may be available in the countries listed below.
Magnesium mixture of several salts (a derivative of Magnesium) is reported as an ingredient of Magnogene in the following countries:
International Drug Name Search
Triamcinolone Hexacetonide may be available in the countries listed below.
Triamcinolone Hexacetonide (BAN, USAN) is known as Triamcinolone in the US.
International Drug Name Search
Glossary
| BAN | British Approved Name |
| USAN | United States Adopted Name |
Amlodipina FG may be available in the countries listed below.
Amlodipine besilate (a derivative of Amlodipine) is reported as an ingredient of Amlodipina FG in the following countries:
International Drug Name Search
Cefotiam Hydrochloride may be available in the countries listed below.
Cefotiam Hydrochloride (BANM, JAN, USAN) is also known as Cefotiam (Rec.INN)
International Drug Name Search
Glossary
| BANM | British Approved Name (Modified) |
| JAN | Japanese Accepted Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
Rifamicina SV Richet may be available in the countries listed below.
Rifamycin sodium salt (a derivative of Rifamycin) is reported as an ingredient of Rifamicina SV Richet in the following countries:
International Drug Name Search
Vetrabutine Hydrochloride may be available in the countries listed below.
Vetrabutine Hydrochloride (BANM) is also known as Vetrabutine (Rec.INN)
International Drug Name Search
Glossary
| BANM | British Approved Name (Modified) |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Fosen may be available in the countries listed below.
Sodium Phosphate Dibasic (a derivative of Sodium Phosphate) is reported as an ingredient of Fosen in the following countries:
Sodium Phosphate Monobasic (a derivative of Sodium Phosphate) is reported as an ingredient of Fosen in the following countries:
International Drug Name Search
Dopamide may be available in the countries listed below.
Methyldopa sesquihydrate (a derivative of Methyldopa) is reported as an ingredient of Dopamide in the following countries:
International Drug Name Search
Liprachol may be available in the countries listed below.
Pravastatin sodium salt (a derivative of Pravastatin) is reported as an ingredient of Liprachol in the following countries:
International Drug Name Search
Ramprazole may be available in the countries listed below.
Rabeprazole is reported as an ingredient of Ramprazole in the following countries:
International Drug Name Search
New Caxon may be available in the countries listed below.
Ascorbic Acid is reported as an ingredient of New Caxon in the following countries:
International Drug Name Search
Prostafin may be available in the countries listed below.
Finasteride is reported as an ingredient of Prostafin in the following countries:
International Drug Name Search
Rocer may be available in the countries listed below.
Omeprazole is reported as an ingredient of Rocer in the following countries:
International Drug Name Search
Generic Name: meclizine (MEK li zeen)
Brand Names: Antivert, Bonine, D-Vert, Dramamine II
Meclizine is an antihistamine that reduces the natural chemical histamine in the body.
Meclizine is used to treat or prevent nausea, vomiting, and dizziness caused by motion sickness. Meclizine is also used to treat symptoms of vertigo.
Meclizine may also be used for other purposes not listed in this medication guide.
Use this medication exactly as directed on the label, or as prescribed by your doctor. Do not use it in larger amounts or for longer than recommended.
Before taking meclizine, tell your doctor if you have asthma or other breathing disorder, glaucoma, an enlarged prostate, or problems with urination.
Cold or allergy medicine, narcotic pain medicine, sleeping pills, muscle relaxers, and medicine for seizures, depression or anxiety can add to sleepiness caused by meclizine. Avoid taking these other medications at the same time you take meclizine.
Before taking meclizine, tell your doctor if you are allergic to any drugs, or if you have:
asthma or other breathing disorder;
glaucoma;
an enlarged prostate; or
problems with urination.
If you have any of these conditions, you may not be able to use this medication, or you may need a dose adjustment or special tests during treatment.
Use this medication exactly as directed on the label, or as prescribed by your doctor. Do not use it in larger amounts or for longer than recommended.
The chewable tablet may be swallowed whole, crushed, or chewed.
To prevent motion sickness, take meclizine about 1 hour before you travel or engage in activity that causes motion sickness. You may take meclizine once every 24 hours while you are traveling, to further prevent motion sickness.
To treat vertigo, you may need to take meclizine several times daily. Follow your doctor's instructions.
Meclizine can cause you to have unusual results with allergy skin tests. Tell any doctor who treats you that you are taking an antihistamine.
Since meclizine is sometimes taken only when needed, you may not be on a dosing schedule. If you are taking the medication regularly, take the missed dose as soon as you remember. If it is almost time for your next dose, wait until then to take the medicine and skip the missed dose. Do not take extra medicine to make up the missed dose.
Overdose symptoms may include extreme drowsiness.
Cold or allergy medicine, narcotic pain medicine, sleeping pills, muscle relaxers, and medicine for seizures, depression or anxiety can add to sleepiness caused by meclizine. Avoid taking these other medications at the same time you take meclizine.
Less serious side effects may include:
blurred vision;
dry mouth;
constipation; or
dizziness, drowsiness.
This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.
There may be other drugs that can interact with meclizine. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.
See also: D-Vert side effects (in more detail)
Irinotecan Pliva may be available in the countries listed below.
Irinotecan hydrochloride trihydrate (a derivative of Irinotecan) is reported as an ingredient of Irinotecan Pliva in the following countries:
International Drug Name Search
Anlos may be available in the countries listed below.
Loratadine is reported as an ingredient of Anlos in the following countries:
International Drug Name Search
Tirdicef may be available in the countries listed below.
Cefotaxime is reported as an ingredient of Tirdicef in the following countries:
International Drug Name Search
Streptokinase Clonbiotech may be available in the countries listed below.
Streptokinase is reported as an ingredient of Streptokinase Clonbiotech in the following countries:
International Drug Name Search
Fosinopril sodium salt (a derivative of Fosinopril) is reported as an ingredient of Fosinopril Sodium and Hydrochlorothiazide in the following countries:
Hydrochlorothiazide is reported as an ingredient of Fosinopril Sodium and Hydrochlorothiazide in the following countries:
International Drug Name Search
Ampicilina Sintesina may be available in the countries listed below.
Ampicillin trihydrate (a derivative of Ampicillin) is reported as an ingredient of Ampicilina Sintesina in the following countries:
International Drug Name Search
Trometamol N may be available in the countries listed below.
Trometamol is reported as an ingredient of Trometamol N in the following countries:
International Drug Name Search
Generic Name: dutasteride and tamsulosin (doo TAS ter ide and tam soo LOE sin)
Brand Names: Jalyn
Dutasteride prevents the conversion of testosterone to dihydrotestosterone (DHT) in the body. DHT is involved in the development of benign prostatic hyperplasia (BPH).
Tamsulosin is in a group of drugs called alpha-adrenergic (AL-fa ad-ren-ER-jik) blockers. Tamsulosin relaxes the muscles in the prostate and bladder neck, making it easier to urinate.
The combination of dutasteride and tamsulosin is used to treat benign prostatic hyperplasia (BPH) in men with an enlarged prostate.
Dutasteride and tamsulosin may also be used for purposes not listed in this medication guide.
Tamsulosin can affect your pupils during cataract surgery. Tell your eye surgeon ahead of time that you are using this medication. Do not stop using dutasteride and tamsulosin before surgery unless your surgeon tells you to.
To make sure you can safely take this medication, tell your doctor if you have any of these other conditions:
low blood pressure;
high blood pressure (hypertension);
liver disease;
severe kidney disease;
a history of prostate cancer; or
if you are allergic to sulfa drugs or to finasteride (Propecia, Proscar).
Tamsulosin can affect your pupils during cataract surgery. Tell your eye surgeon ahead of time that you are using this medication. Do not stop using dutasteride and tamsulosin before surgery unless your surgeon tells you to.
Take exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.
To be sure this medication is helping your condition and not causing harmful effects, your blood may need to be tested often. Your doctor will also test your prostate specific antigen (PSA) to check for prostate cancer. Visit your doctor regularly.
See also: Dutasteride and tamsulosin dosage (in more detail)
Take the missed dose 30 minutes after your next meal. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.
If you miss your doses for several days in a row, contact your doctor before restarting the medication. You may need a lower dose.
Overdose symptoms may include extreme dizziness or fainting.
Avoid getting up too fast from a sitting or lying position, or you may feel dizzy. Get up slowly and steady yourself to prevent a fall.
feeling like you might pass out; or
penis erection that is painful or lasts 4 hours or longer.
Less serious side effects may include:
decreased libido (sex drive);
decreased amount of semen released during sex;
impotence (trouble getting or keeping an erection);
breast tenderness or enlargement;
mild dizziness; or
runny nose.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Usual Adult Dose for Benign Prostatic Hyperplasia:
dutasteride-tamsulosin 0.5 mg-0.4 mg capsule orally once daily approximately 30 minutes after the same meal each day
Tell your doctor about all other medications you use, especially:
cimetidine (Tagamet);
conivaptan (Vaprisol);
cyclosporine (Gengraf, Neoral, Sandimmune);
imatinib (Gleevec);
isoniazid (for treating tuberculosis);
methimazole (Tapazole);
pioglitazone (Actos);
ropinirole (Requip);
ticlopidine (Ticlid);
a blood thinner such as warfarin (Coumadin, Jantoven);
an antibiotic such as clarithromycin (Biaxin), doxycycline (Adoxa, Alodox, Avidoxy, Oraxyl, Doryx, Oracea, Vibramycin), erythromycin (E.E.S., EryPed, Ery-Tab, Erythrocin, Pediazole), metronidazole (Flagyl, Protostat), telithromycin (Ketek), terbinafine (Lamisil), or tetracycline (Ala-Tet, Brodspec, Panmycin, Sumycin, Tetracap);
an antidepressant such as clomipramine (Anafranil), desipramine (Norpramin), duloxetine (Cymbalta), fluoxetine (Prozac, Sarafem), nefazodone, paroxetine (Paxil), sertraline (Zoloft), tranylcypromine (Parnate), or trazodone (Desyrel, Oleptro);
antifungal medication such as fluconazole (Diflucan), itraconazole (Sporanox), ketoconazole (Nizoral), miconazole (Oravig), or voriconazole (Vfend);
anti-malaria medication such as chloroquine (Arelan) or pyrimethamine (Daraprim), or quinine (Qualaquin);
erectile dysfunction medicine such as sildenafil (Viagra), tadalafil (Cialis), or vardenafil (Levitra);
heart or blood pressure medication such as amiodarone (Cordarone, Pacerone), nicardipine (Cardene), or quinidine (Quin-G), and others;
HIV/AIDS medicine such as atazanavir (Reyataz), delavirdine (Rescriptor), efavirenz (Sustiva), fosamprenavir (Lexiva), indinavir (Crixivan), nelfinavir (Viracept), saquinavir (Invirase), or ritonavir (Norvir); or
medicine to treat psychiatric disorders, such as aripiprazole (Abilify), chlorpromazine (Thorazine), clozapine (Clozaril, FazaClo), fluphenazine (Permitil, Prolixin), haloperidol (Haldol), perphenazine (Trilafon), or thioridazine (Mellaril).
See also: dutasteride and tamsulosin side effects (in more detail)
Remac may be available in the countries listed below.
Clarithromycin is reported as an ingredient of Remac in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
In the US, Numorphan (oxymorphone systemic) is a member of the drug class narcotic analgesics and is used to treat Labor Pain and Pain.
US matches:
Oxymorphone hydrochloride (a derivative of Oxymorphone) is reported as an ingredient of Numorphan in the following countries:
International Drug Name Search
Reflon may be available in the countries listed below.
Glucosamine hydrochloride (a derivative of Glucosamine) is reported as an ingredient of Reflon in the following countries:
International Drug Name Search
Locorten may be available in the countries listed below.
Clioquinol is reported as an ingredient of Locorten in the following countries:
Flumetasone 21-pivalate (a derivative of Flumetasone) is reported as an ingredient of Locorten in the following countries:
Neomycin sulfate (a derivative of Neomycin) is reported as an ingredient of Locorten in the following countries:
International Drug Name Search
Winperid may be available in the countries listed below.
Risperidone is reported as an ingredient of Winperid in the following countries:
International Drug Name Search
Ozen may be available in the countries listed below.
Cetirizine dihydrochloride (a derivative of Cetirizine) is reported as an ingredient of Ozen in the following countries:
International Drug Name Search
Sifloks may be available in the countries listed below.
Ciprofloxacin is reported as an ingredient of Sifloks in the following countries:
Ciprofloxacin hydrochloride (a derivative of Ciprofloxacin) is reported as an ingredient of Sifloks in the following countries:
International Drug Name Search
Heptanon may be available in the countries listed below.
Methadone hydrochloride (a derivative of Methadone) is reported as an ingredient of Heptanon in the following countries:
International Drug Name Search
Trazodon-neuraxpharm may be available in the countries listed below.
Trazodone hydrochloride (a derivative of Trazodone) is reported as an ingredient of Trazodon-neuraxpharm in the following countries:
International Drug Name Search
Cardival may be available in the countries listed below.
Valsartan is reported as an ingredient of Cardival in the following countries:
International Drug Name Search
Losartan-Mepha plus may be available in the countries listed below.
Hydrochlorothiazide is reported as an ingredient of Losartan-Mepha plus in the following countries:
Losartan potassium salt (a derivative of Losartan) is reported as an ingredient of Losartan-Mepha plus in the following countries:
International Drug Name Search
Dermeol may be available in the countries listed below.
Dodeclonium Bromide is reported as an ingredient of Dermeol in the following countries:
Enoxolone is reported as an ingredient of Dermeol in the following countries:
International Drug Name Search
In the US, Ten-K is a member of the drug class minerals and electrolytes and is used to treat Hypokalemia and Prevention of Hypokalemia.
Potassium Chloride is reported as an ingredient of Ten-K in the following countries:
International Drug Name Search
Doxy S+K Aknetabs may be available in the countries listed below.
Doxycycline monohydrate (a derivative of Doxycycline) is reported as an ingredient of Doxy S+K Aknetabs in the following countries:
International Drug Name Search
Speedfen may be available in the countries listed below.
Dexibuprofen is reported as an ingredient of Speedfen in the following countries:
International Drug Name Search
Citicoline S may be available in the countries listed below.
Citicoline is reported as an ingredient of Citicoline S in the following countries:
International Drug Name Search
In some countries, this medicine may only be approved for veterinary use.
In the US, Ranitidine (ranitidine systemic) is a member of the drug class H2 antagonists and is used to treat Duodenal Ulcer, Duodenal Ulcer Prophylaxis, Erosive Esophagitis, Gastric Ulcer Maintenance Treatment, Gastrointestinal Hemorrhage, GERD, Indigestion, Pathological Hypersecretory Conditions, Stomach Ulcer, Stress Ulcer Prophylaxis, Surgical Prophylaxis and Zollinger-Ellison Syndrome.
US matches:
UK matches:
Rec.INN
A02BA02
0066357-35-5
C13-H22-N4-O3-S
314
Gastric acid secretion inhibitor
Histamine, H₂-receptor antagonist
Treatment of peptic ulcer and gastro-oesophageal reflux disease (GORD)
1,1-Ethenediamine, N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-
